Form 8-K ROCKWELL MEDICAL, INC. For: Nov 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Chardan Capital Still Positive on Rockwell Medical (RMTI) Following Q3 Results, Update
November 11, 2014 7:55 AM ESTChardan Capital affirms Rockwell Medical Technologies (Nasdaq: RMTI) at Buy with a price target of $27 following Q3 results.
Analyst Ling Wang noted that RMTI's loss of $0.10 per share was roughly in-line with the firm's $0.11 per share loss estimate.
Wang offered the following commentary:
FDA ODAC panel posted majority vote favoring the approval of Triferic. Last Wednesday, the ODAC panel voted favorably for the approval of RMTI's Triferic... More
